In this video, InMed CEO Eric A. Adams speaks with BTV about InMed’s focus on cannabinoid-based pharmaceutical products. Mr. Adams talks about the company’s proprietary biosynthesis platform with potential to manufacture pharmaceutical-grade, high-yield cannabinoids.
What quality controls should be put in place to ensure consistency and purity of cannabinoids for CPG products?
Dr. Shane Johnson, GM of BayMedica, InMed’s subsidiary, answers these questions: What is the minimum GMP standard that consumers should expect? What quality controls should